tbuckley/cabot-search huggingface dataset:
Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants
Authors: Xiaohua Gong, Ling Peng, Fuxiang Wang, Jiexiang Liu, Yimin Tang, Yun Peng, Shiyu Niu, Juzhen Yin, Liping Guo, Hongzhou Lu, Yingxia Liu, Yang Yang
Journal: Journal of Infection (2024)

ObjectiveSimilar with influenza virus, antigenic drift is highly relevant to SARS-CoV-2 evolution, and immune imprinting has been found to limit the performance of updated vaccines based on the emerging variants of SARS-CoV-2. We aimed to investigate whether repeated exposure to Omicron variant could reduce the immune imprinting from previous vaccination.MethodsA total of 194 participants with different status of vaccination (unvaccinated, regular vaccination and booster vaccination) confirmed for first infection and re-infection with BA.5, BF.7 and XBB variants were enrolled, and the neutralizing profiles against wild type (WT) SARS-CoV-2 and Omicron sub-variants were analyzed.ResultsNeutralizing potency against the corresponding infected variant is significantly hampered along with the doses of vaccination during first infection. However, for the participants with first infection of BA.5/BF.7 variants and re-infection of XBB variant, immune imprinting was obviously alleviated, indicated as significantly increased ratio of the corresponding infected variant/WT ID50 titers and higher percentage of samples with high neutralizing activities (ID50>500) against BA.5, BF.7 and XBB variants. Moreover, repeated Omicron infection could induce strong neutralizing potency with broad neutralizing profiles against a series of other Omicron sub-variants, both in the vaccine naive and vaccine experienced individuals.ConclusionsOur results demonstrate that repeated Omicron infection dampens immune imprinting from vaccination with WT SARS-CoV-2 and induces broad neutralizing profiles against Omicron sub-variants.
Exportin 1 governs the immunosuppressive functions of myeloid-derived suppressor cells in tumors through ERK1/2 nuclear export
Authors: Saeed Daneshmandi, Qi Yan, Jee Eun Choi, Eriko Katsuta, Cameron R. MacDonald, Mounika Goruganthu, Nathan Roberts, Elizabeth A. Repasky, Prashant K. Singh, Kristopher Attwood, Jianmin Wang, Yosef Landesman, Philip L. McCarthy, Hemn Mohammadpour
Journal: Cellular and Molecular Immunology (2024)
High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy
Authors: Rong Fan, Siru Zhao, Junqi Niu, Hong Ma, Qing Xie, Song Yang, Jianping Xie, Xiaoguang Dou, Jia Shang, Huiying Rao, Qi Xia, Yali Liu, Yongfeng Yang, Hongbo Gao, Aimin Sun, Xieer Liang, Xueru Yin, Yongfang Jiang, Yanyan Yu, Jian Sun, Nikolai V Naoumov, Jinlin Hou
Journal: Gut (2024)

Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but this rarely occurs with currently approved therapies. We aimed to develop and validate a prognostic model for HBsAg loss on treatment using longitudinal data from a large, prospectively followed, nationwide cohort.
Assessment of the Predictive Ability of Theranostics for Corneal Cross-linking in Treating Keratoconus
Authors: Anna Maria Roszkowska, Vincenzo Scorcia, Rita Mencucci, Giuseppe Giannaccare, Giuseppe Lombardo, Danilo Alunni Fegatelli, Annarita Vestri, Luca Bifezzi, Giuseppe Massimo Bernava, Sebastiano Serrao, Marco Lombardo
Journal: Ophthalmology (2024)
Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis
Authors: Juan Berenguer, José M. Bellón, Rafael Bañares, Juan González-García
Journal: Hepatology (2024)

Berenguer, Juan; Bellón, José M.; Bañares, Rafael; González-García, Juan Author Information
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse
Authors: Meilin Yang, Xiaoyi Song, Fan Zhang, Mingan Li, Wuguang Chang, Zheyan Wang, Man Li, Hong Shan, Dan Li
Journal: Hepatology (2024)

Background and Aims: Surgical resection serves as the principal curative strategy for HCC, yet the incidence of postoperative recurrence remains alarmingly high. However, the spatial molecular structural alterations contributing to postoperative recurrence in HCC are still poorly understood. Approach and Results: We employed imaging mass cytometry to profile the in situ expression of 33 proteins within 358,729 single cells of 92 clinically annotated surgical specimens from 46 patients who were treated with surgical resections for primary and relapsed tumors. We revealed the recurrence progression of HCC was governed by the dynamic spatial distribution and functional interplay of diverse cell types across adjacent normal, tumor margin, and intratumor regions. Our exhaustive analyses revealed an aggressive, immunosuppression-related spatial ecosystem in relapsed HCC. Additionally, we illustrated the prominent implications of the tumor microenvironment of tumor margins in association with relapse HCC. Moreover, we identified a novel subpopulation of dendritic cells (PDL1 + CD103 + DCs) enriched in the peritumoral area that correlated with early postoperative recurrence, which was further validated in an external cohort. Through the analysis of single-cell RNA sequencing data, we found the interaction of PDL1 + CD103 + DCs with regulatory T cells and exhausted T cells enhanced immunosuppression and immune escape through multiple ligand-receptor pathways. Conclusions: We comprehensively depicted the spatial landscape of single-cell dynamics and multicellular architecture within primary and relapsed HCC. Our findings highlight spatial organization as a prominent determinant of HCC recurrence and provide valuable insight into the immune evasion mechanisms driving recurrence.
Genetic predisposition to porto-sinusoidal vascular disorder
Authors: Nadia Ciriaci, Lise Bertin, Pierre-Emmanuel Rautou
Journal: Hepatology (2024)

Porto-sinusoidal vascular disorder (PSVD) is a rare liver disease. The pathophysiological mechanisms underlying the development of PSVD are unknown. Isolated cases of PSVD associated with gene mutations have been reported, but no overview is available. Therefore, we performed an extensive literature search to provide a comprehensive overview of gene mutations associated with PSVD. We identified 34 genes and 1 chromosomal abnormality associated with PSVD in the literature, and we describe here 1 additional gene mutation ( TBL1XR1 mutation, leading to Pierpont syndrome). These gene mutations are associated either with extrahepatic organ involvement as part of syndromes (Adams-Oliver, telomere biology disorders, retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations, immune deficiencies, cystic fibrosis, cystinosis, Williams-Beuren, Turner, Pierpont) or with isolated PSVD ( KCNN3 , DGUOK , FOPV , GIMAP5 , FCHSD1 , TRMT5 , HRG gene mutations). Most of the cases were revealed by signs or complications of portal hypertension. When analyzing the cell types in which these genes are expressed, we found that these genes are predominantly expressed in immune cells, suggesting that these cells may play a more important role in the development of PSVD than previously thought. In addition, pathway analyses suggested that there may be 2 types of PSVD associated with gene mutations: those resulting directly from morphogenetic abnormalities and those secondary to immune changes.
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer
Authors: Nicolás Gómez-Banoy, Eduardo J. Ortiz, Caroline S. Jiang, Christian Dagher, Carlo Sevilla, Jeffrey Girshman, Andrew M. Pagano, Andrew J. Plodkowski, William A. Zammarrelli, Jennifer J. Mueller, Carol Aghajanian, Britta Weigelt, Vicky Makker, Paul Cohen, Juan C. Osorio
Journal: Journal of Clinical Investigation (2024)

BACKGROUNDObesity is the foremost risk factor in the development of endometrial cancer (EC). However, the impact of obesity on the response to immune checkpoint inhibitors (ICI) in EC remains poorly understood. This retrospective study investigates the association among BMI, body fat distribution, and clinical and molecular characteristics of EC patients treated with ICI.METHODSWe analyzed progression-free survival (PFS) and overall survival (OS) in EC patients treated with ICI, categorized by BMI, fat-mass distribution, and molecular subtypes. Incidence of immune-related adverse events (irAEs) after ICI was also assessed based on BMI status.RESULTS524 EC patients were included in the study. Overweight and obese patients exhibited a significantly prolonged PFS and OS compared with normal BMI patients after treatment with ICI. Multivariable Cox's regression analysis confirmed the independent association of overweight and obesity with improved PFS and OS. Elevated visceral adipose tissue (VAT) was identified as a strong independent predictor for improved PFS to ICI. Associations between obesity and OS/PFS were particularly significant in the copy number-high/TP53abnormal (CN-H/TP53abn) EC molecular subtype. Finally, obese patients demonstrated a higher irAE rate compared with normal BMI individuals.CONCLUSIONObesity is associated with improved outcomes to ICI in EC patients and a higher rate of irAEs. This association is more pronounced in the CN-H/TP53abn EC molecular subtype.FUNDINGNIH/NCI Cancer Center; MSK Gerstner Physician Scholars Program; National Center for Advancing Translational Sciences (NCATS); Cycle for Survival; Breast Cancer Research Foundation.
Androgen aggravates aortic aneurysms via suppressing PD-1 in mice
Authors: Xufang Mu, Shu Liu, Zhuoran Wang, Kai Jiang, Tim McClintock, Arnold J. Stromberg, Alejandro V. Tezanos, Eugene S. Lee, John A. Curci, Ming C. Gong, Zhenheng Guo
Journal: Journal of Clinical Investigation (2024)

Androgen has long been recognized for its pivotal role in the sexual dimorphism of cardiovascular diseases, including aortic aneurysms, a devastating vascular disease with a higher prevalence and fatality rate in men than women. However, the mechanism by which androgen mediates aortic aneurysms is largely unknown. Herein, we found that male mice, not female mice, developed aortic aneurysms when exposed to aldosterone and high salt (Aldo-salt). We revealed that androgen and androgen receptors (AR) were crucial for this sexually dimorphic response to Aldo-salt. We identified programmed cell death protein 1 (PD-1), an immune checkpoint, as a key link between androgen and aortic aneurysms. We demonstrated that administration of anti-PD-1 Ab and adoptive PD-1 deficient T cell transfer reinstated Aldo-salt-induced aortic aneurysms in orchiectomized mice, and genetic deletion of PD-1 exacerbated aortic aneurysms induced by high-fat diet and angiotensin II (Ang II) in non-orchiectomized mice. Mechanistically, we discovered that AR bound to the PD-1 promoter to suppress its expression in the spleen. Thus, our study unveils a mechanism by which androgen aggravates aortic aneurysms by suppressing PD-1 expression in T cells. Moreover, our study suggests that some cancer patients might benefit from screenings for aortic aneurysms during immune checkpoint therapy.
Houde CA, Khan A, Jacobus SJ, et al. Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus Rvd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (Pts) with newly diagnosed multiple myeloma (NDMM) in the Determination phase 3 trial [abstract]. <i>Blood.</i> 2023;142(suppl 1):4762.
Journal: Blood (2024)
Garcia E, Horowitz AM, Franklin K, Mader M, Kaur S. Outcomes of veterans with FMS-like tyrosine kinase 3 mutated (mFLT3) acute myeloid leukemia (AML) treated with novel FLT3 inhibitors (FLT3i) within the Veterans Health Administration (VHA) [abstract]. <i>Blood</i>. 2023;142(suppl 1):7414.
Journal: Blood (2024)
Piercing the Fog
Authors: Antonio Yaghy
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Authors: Michael Cecchini, Ronald R. Salem, Marie Robert, Suzanne Czerniak, Ondrej Blaha, Daniel Zelterman, Moein Rajaei, Jeffrey P. Townsend, Guoping Cai, Sumedha Chowdhury, Deanne Yugawa, Robert Tseng, Carlos Mejia Arbelaez, Jingjing Jiao, Kenneth Shroyer, Jaykumar Thumar, Jeremy Kortmansky, Wajih Zaheer, Neal Fischbach, Justin Persico, Stacey Stein, Sajid A. Khan, Charles Cha, Kevin G. Billingsley, John W. Kunstman, Kimberly L. Johung, Christina Wiess, Mandar D. Muzumdar, Erik Spickard, Vasily N. Aushev, George Laliotis, Adham Jurdi, Minetta C. Liu, Luisa Escobar-Hoyos, Jill Lacy
Journal: JAMA Oncology (2024)

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant tumor, and durable disease control is rare with the current standard of care, even for patients who undergo surgical resection.
Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials
Authors: Timothée Olivier, Alyson Haslam, Vinay Prasad
Journal: JAMA Oncology (2024)

Importance In oncology randomized clinical trials, suboptimal access to best available care at recurrence (or relapse) may affect overall survival results. Objective To assess the proportion and the quality of postrecurrence treatment received by patients enrolled in US Food and Drug Administration (FDA) registration trials of systemic therapy in the adjuvant or neoadjuvant setting. Evidence Review For this systematic review, all trials leading to an FDA approval from January 2018 through May 2023 were obtained from the FDA website and drug announcements. Randomized clinical trials of an anticancer drug in the neoadjuvant or the adjuvant setting were included. Trials of supportive care treatment and treatments given in combination with radiotherapy were excluded. Information abstracted for each trial included tumor type, setting, phase, type of sponsor, reporting and assessment of postrecurrence, and overall survival data. Findings A total of 14 FDA trials met the inclusion criteria. Postrecurrence data were not available in 6 of 14 registration trials (43%). Of the 8 remaining trials, postrecurrence treatment was assessed as suboptimal in 6 (75%). Overall, only 2 of 14 trials (14%) had data assessed as appropriate. Conclusions and Relevance This systematic review found that 43% of randomized clinical trials of anticancer treatment in the adjuvant or neoadjuvant context failed to present any assessable postrecurrence treatment data. In instances in which these data were shared, postrecurrence treatment was suboptimal 75% of the time. The findings suggest that regulatory bodies should enforce rules stipulating that patients have access to the best standard of care at recurrence.
free flap
Authors: Tega Ebeye
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Loneliness, Lack of Social and Emotional Support, and Mental Health Issues — United States, 2022
Authors: Katherine V. Bruss, Puja Seth, Guixiang Zhao
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Loneliness and isolation are indicators of social disconnection that can lead to poor mental and physical health outcomes, including increased risk for heart disease, stroke, dementia, type 2 diabetes, depression, anxiety, and premature mortality (1-3).Although these risks are well documented, a more comprehensive understanding of the impact of loneliness and lack of social and emotional support on mental health-related outcomes is needed, particularly among persons experiencing the most social disconnection, such as those who do not identify as heterosexual and cisgender.Sexual and gender minority (SGM) data are often not collected in research, resulting in a lack of data on and evidence-based interventions for loneliness and lack of social and emotional support among these groups (4,5).The objectives of this study were to assess the association between social connection and mental health among U.S. adults and to determine the prevalence of loneliness, lack of
Emergency Medical Services Encounters for Firearm Injuries — 858 Counties, United States, January 2019–September 2023
Authors: Adam Rowh, Marissa Zwald, Katherine Fowler, Shane Jack, Carlos Siordia, Josh Walters
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Firearm-related deaths and injuries have increased in recent years.Comprehensive and timely information on firearm injuries and the communities and geographic locations most affected by firearm violence is crucial for guiding prevention activities.However, traditional surveillance systems for firearm injury, which are mostly based on hospital encounters and mortality-related data, often lack information on the location where the shooting occurred.This study examined annual and monthly rates of emergency medical services (EMS) encounters for firearm injury per 100,000 total EMS encounters during January 2019-September 2023 in 858 counties in 27 states, by patient characteristics and characteristics of the counties where the injuries occurred.Overall, annual rates of firearm injury EMS encounters per 100,000 total EMS encounters ranged from 222.7 in 2019 to 294.9 in 2020; rates remained above prepandemic levels through 2023.Rates were consistently higher among males than females.Rates stratified by race and ethnicity were highest among non-Hispanic Black or African American persons; rates stratified by age group were highest among persons aged 15-24 years.The greatest percentage increases in annual rates occurred in urban counties and in counties with higher prevalence of severe housing problems, higher income inequality ratios, and higher rates of unemployment.States and communities can use the timely and location-specific data in EMS records to develop and implement comprehensive firearm injury prevention strategies to address the economic, social, and physical conditions that contribute to the risk for violence, including improvements to physical environments, secure firearm storage, and strengthened social and economic supports.* https://wonder.cdc.gov(Accessed April 5, 2024).department (ED) visits were 37%, 36%, and 20% higher, respectively (1).Syndromic surveillance of firearm-related injuries assessed in EDs has provided timely monitoring of trends, especially during the COVID-19 pandemic (1,2).Prehospital services (i.e., emergency medical services [EMS]) data have complemented ED surveillance of other injuries and conditions, including opioid overdoses (3).However, use of EMS encounter data to understand trends in firearm injuries is currently limited.EMS encounter data can provide information on the geographic location where firearm injury incidents occur, information that is often unavailable in hospital-based or mortality-related data sources and which could allow more refined analyses of social determinants of health associated with firearm injuries (4-6).Further, EMS encounter data capture nonfatal firearm injuries in persons who refuse or do not seek hospital-based care.This report describes trends in the rates of firearm injuries by selected patient-and county-level characteristics using EMS encounter data during January
Photoactivated growth factor release from bio-orthogonally crosslinked hydrogels for the regeneration of corneal defects
Authors: Nae-Won Kang, Youngyoon Amy Seo, Kevin J Jackson, Kyeongwoo Jang, Euisun Song, Uiyoung Han, Fang Chen, Sarah C Heilshorn, David Myung
Journal: Bioactive Materials (2024)
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Authors: Mingke Ni, Ziv Dadon, Julian O. M. Ormerod, Johan Saenen, Wiert F. Hoeksema, Pavel Antiperovitch, Rafik Tadros, Morten K. Christiansen, Christian Steinberg, Marine Arnaud, Shanshan Tian, Bo Sun, John Paul Estillore, Ruiwu Wang, Habib R. Khan, Thomas M. Roston, Andrea Mazzanti, John R. Giudicessi, Konstantinos C. Siontis, Aiman Alak, J. Gabriel Acosta, Syamkumar M. Divakara Menon, Nigel S. Tan, Christian van der Werf, Babak Nazer, Hari Vivekanantham, Tanvi Pandya, Jennifer Cunningham, Lorne J. Gula, Jorge A. Wong, Guy Amit, Melvin M. Scheinman, Andrew D. Krahn, Michael J. Ackerman, Silvia G. Priori, Michael H. Gollob, Jeff S. Healey, Frederic Sacher, Eyal Nof, Michael Glikson, Arthur A. M. Wilde, Hugh Watkins, Henrik K. Jensen, Pieter G. Postema, Bernard Belhassen, S. R. Wayne Chen, Jason D. Roberts
Journal: JAMA (2024)

Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest.
Use of a Financial Incentive Code for In-Home COVID-19 Vaccination of Homebound Older Adults
Authors: Robert M. Zimbroff, W. James Deardorff, Sujin Song, Margaret C. Nikolov, Matthew E. Growdon
Journal: JAMA (2024)

This study evaluated the uptake of Healthcare Common Procedure Coding System code M0201 after initial implementation to inform future policy related to in-home preventive care.